All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Retrospective analysis of bendamustine plus rituximab versus R-CHOP in grade 3A FL
Patrizia Mondello of University of Messina, in Messina Italy, and colleagues published results of a retrospective subgroup analysis comparing bendamustine plus rituximab (B-R) to standard rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP) therapy for patients with grade 3A follicular lymphoma. The results were published in the January 9, 2018 issue of The Oncologist journal.
Follicular lymphoma is the most common type of indolent lymphoma. Among histological grades 1, 2, and 3, grade 3 is the most aggressive. Two trials published in the last several years have demonstrated improved outcomes and less toxicity with R-CHOP therapy compared to bendamustine plus rituximab for lymphoma. This analysis of a randomized trial is the first published data to compare the two treatment regimens in grade 3A follicular lymphoma (FL3A).
Patient Population
- N = 132 patients
- Median age
- B-R: 63 years vs. R-CHOP: 57 years
- Ki67 >30%
- B-R: 45% vs. R-CHOP: 19%
- Bone marrow involvement
- B-R: 59% vs. R-CHOP: 11%
Key Findings
- ORR, CR, SD the same in both groups
- Dose reductions
- B-R: 1% vs. R-CHOP: 12%
- Adverse events
- Neutropenia: B-R: 6% vs. R-CHOP: 30%
- Infections: B-R: 5% vs. R-CHOP: 35%
- Anemia: B-R: 2% vs. R-CHOP: 13%
- Thrombocytopenia: B-R: 5% vs. R-CHOP: 16%
- Peripheral neuropathy: B-R: 1% vs.R-CHOP: 45%
- Rash: B-R: 3% vs. R-CHOP: 15%
- Secondary malignancy: B-R: 3% vs. R-CHOP: 13%
- 15-year follow-up outcomes
- Relapse: B-R: 16% vs. R-CHOP: 41%
- Death: B-R: 6% vs. R-CHOP: 20%
- Progression-free survival: B-R: 15 years vs. R-CHOP: 11.7 years
This data represents an option for providing favorable outcomes and reduced toxicity for patients with grade 3A follicular lymphoma. Treatment with bendamustine plus rituximab also provides a long-term survival benefit, with reduced rates of relapse, death and disease progression. Bendumustine plus rituximab represents a very viable treatment option for FL3A patients.
References
Your opinion matters
What types of support services or resources do you think would best facilitate the safe implementation of the BrECADD regimen in clinical practice?